The estimated Net Worth of Thomas W Hawkeswood is at least $609 ezer dollars as of 23 August 2023. Thomas Hawkeswood owns over 147 units of Catalent stock worth over $449,193 and over the last 2 years Thomas sold CTLT stock worth over $160,128.
Thomas has made over 4 trades of the Catalent stock since 2022, according to the Form 4 filled with the SEC. Most recently Thomas sold 147 units of CTLT stock worth $6,574 on 23 August 2023.
The largest trade Thomas's ever made was selling 930 units of Catalent stock on 10 October 2022 worth over $72,038. On average, Thomas trades about 502 units every 91 days since 2022. As of 23 August 2023 Thomas still owns at least 7,533 units of Catalent stock.
You can see the complete history of Thomas Hawkeswood stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET, NJ, 08873.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius és Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: